Merck stock price target lowered to $95 by Bernstein SocGen
Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...
Jim Cramer Discusses These 12 Stocks & An Outfit Better Than DeepSeek
In this piece, we will look at the stocks Jim Cramer recently discussed.
Hosted on MSN22h
Wall Street Predict 92% Upside for This Dividend Stock: Should You Buy It Now?
Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.
Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund
In this piece, we will look at the stocks Jim Cramer recently discussed.
pharmaphorum23h
ASCO: Moderna, Merck melanoma vaccine set for phase 3
Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase ...